JP6629884B2 - 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニル−３ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体 - Google Patents
哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニル−３ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体 Download PDFInfo
- Publication number
- JP6629884B2 JP6629884B2 JP2017558782A JP2017558782A JP6629884B2 JP 6629884 B2 JP6629884 B2 JP 6629884B2 JP 2017558782 A JP2017558782 A JP 2017558782A JP 2017558782 A JP2017558782 A JP 2017558782A JP 6629884 B2 JP6629884 B2 JP 6629884B2
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- amino
- pyridin
- chloro
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *Cc1ccccc1 Chemical compound *Cc1ccccc1 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153394 | 2015-02-02 | ||
| EP15153394.0 | 2015-02-02 | ||
| PCT/EP2016/052091 WO2016124553A1 (en) | 2015-02-02 | 2016-02-01 | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507255A JP2018507255A (ja) | 2018-03-15 |
| JP2018507255A5 JP2018507255A5 (https=) | 2019-02-28 |
| JP6629884B2 true JP6629884B2 (ja) | 2020-01-15 |
Family
ID=52449976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558782A Expired - Fee Related JP6629884B2 (ja) | 2015-02-02 | 2016-02-01 | 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニル−３ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10550113B2 (https=) |
| EP (1) | EP3253754B1 (https=) |
| JP (1) | JP6629884B2 (https=) |
| KR (1) | KR102493943B1 (https=) |
| CN (1) | CN107567445B (https=) |
| AU (1) | AU2016214492B2 (https=) |
| BR (1) | BR112017016428B1 (https=) |
| CA (1) | CA2973773C (https=) |
| ES (1) | ES2875737T3 (https=) |
| IL (1) | IL253380B (https=) |
| MX (1) | MX374552B (https=) |
| WO (1) | WO2016124553A1 (https=) |
| ZA (1) | ZA201705933B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660303B2 (en) | 2016-07-11 | 2023-05-30 | Kancera Ab | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity |
| CN109563092B (zh) * | 2016-07-11 | 2021-09-14 | 坎塞拉有限公司 | 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物 |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| JP7378267B2 (ja) | 2018-11-12 | 2023-11-13 | 東ソー株式会社 | コバルト錯体、その製造方法、及びコバルト含有薄膜の製造方法 |
| JP7641902B2 (ja) | 2019-01-29 | 2025-03-07 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | 緑内障の新規治療法 |
| CN112574176B (zh) * | 2019-09-27 | 2024-03-15 | 隆泰申医药科技(南京)有限公司 | 一种杂芳基类化合物及其应用 |
| CN117049977A (zh) * | 2023-08-16 | 2023-11-14 | 四川伊诺达博医药科技有限公司 | 一种n-乙基-2-(4-甲酰基苯基)乙酰胺的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002349477A1 (en) | 2001-11-26 | 2003-06-10 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| SE0202462D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| SE0202464D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Use of compounds |
| US7618964B2 (en) | 2004-12-23 | 2009-11-17 | Hoffmann-La Roche Inc. | Benzamide derivatives, their manufacture and use as pharmaceutical agents |
| US7786113B2 (en) | 2004-12-23 | 2010-08-31 | Hoffman-La Roche Inc. | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents |
| PL1861387T3 (pl) | 2005-01-28 | 2014-08-29 | Dae Woong Pharma | Pochodne benzoimidazolu i ich kompozycje farmaceutyczne |
| EP1891069A1 (en) | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| EP1963315B1 (en) | 2005-12-22 | 2014-10-08 | Cancer Research Technology Limited | Enzyme inhibitors |
| US20090170847A1 (en) | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
| RU2009135616A (ru) | 2007-03-30 | 2011-05-10 | Астразенека Аб (Se) | НОВЫЕ АМИДАЗО[4,5-b]ПИРИДИН-7-КАРБОКСАМИДЫ 704 |
| WO2008121064A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705 |
| WO2009001021A1 (en) | 2007-06-26 | 2008-12-31 | Chroma Therapeutics Ltd. | Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases |
| ES2392482T3 (es) | 2008-02-29 | 2012-12-11 | Array Biopharma, Inc. | Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF |
| WO2011066211A1 (en) | 2009-11-24 | 2011-06-03 | Glaxosmithkline Llc | Azabenzimidazoles as fatty acid synthase inhibitors |
| EP2513146B1 (en) | 2009-12-18 | 2017-05-03 | Kancera AB | Antibodies against ror1 capable of inducing cell death of cll |
| ES2567552T3 (es) * | 2012-01-30 | 2016-04-25 | Cephalon, Inc. | Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos |
-
2016
- 2016-02-01 EP EP16702147.6A patent/EP3253754B1/en active Active
- 2016-02-01 JP JP2017558782A patent/JP6629884B2/ja not_active Expired - Fee Related
- 2016-02-01 AU AU2016214492A patent/AU2016214492B2/en not_active Ceased
- 2016-02-01 ES ES16702147T patent/ES2875737T3/es active Active
- 2016-02-01 CN CN201680008251.1A patent/CN107567445B/zh not_active Expired - Fee Related
- 2016-02-01 US US15/545,523 patent/US10550113B2/en active Active
- 2016-02-01 KR KR1020177024661A patent/KR102493943B1/ko active Active
- 2016-02-01 MX MX2017009600A patent/MX374552B/es active IP Right Grant
- 2016-02-01 BR BR112017016428-0A patent/BR112017016428B1/pt not_active IP Right Cessation
- 2016-02-01 WO PCT/EP2016/052091 patent/WO2016124553A1/en not_active Ceased
- 2016-02-01 CA CA2973773A patent/CA2973773C/en active Active
-
2017
- 2017-07-10 IL IL253380A patent/IL253380B/en unknown
- 2017-08-31 ZA ZA2017/05933A patent/ZA201705933B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX374552B (es) | 2025-03-06 |
| CN107567445A (zh) | 2018-01-09 |
| US10550113B2 (en) | 2020-02-04 |
| JP2018507255A (ja) | 2018-03-15 |
| ES2875737T3 (es) | 2021-11-11 |
| KR102493943B1 (ko) | 2023-01-31 |
| AU2016214492B2 (en) | 2020-05-07 |
| KR20170113629A (ko) | 2017-10-12 |
| WO2016124553A1 (en) | 2016-08-11 |
| HK1247923A1 (zh) | 2018-10-05 |
| EP3253754B1 (en) | 2021-03-31 |
| EP3253754A1 (en) | 2017-12-13 |
| BR112017016428B1 (pt) | 2023-10-24 |
| CA2973773C (en) | 2023-10-17 |
| BR112017016428A2 (pt) | 2018-04-10 |
| IL253380A0 (en) | 2017-09-28 |
| MX2017009600A (es) | 2017-11-22 |
| AU2016214492A1 (en) | 2017-08-24 |
| US20180002329A1 (en) | 2018-01-04 |
| CA2973773A1 (en) | 2016-08-11 |
| IL253380B (en) | 2021-07-29 |
| CN107567445B (zh) | 2021-06-29 |
| ZA201705933B (en) | 2018-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6629884B2 (ja) | 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニル−３ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体 | |
| CN113490495B (zh) | Helios的小分子降解剂及其使用方法 | |
| JP6553236B2 (ja) | Ｃｃ９アンタゴニストとしてのピラゾール−１−イルベンゼンスルホンアミド | |
| JP5306344B2 (ja) | 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド | |
| CN109195602B (zh) | 用作免疫调节剂的对称或半对称化合物 | |
| JP6458023B2 (ja) | 繊維芽細胞成長因子受容体の阻害剤 | |
| RU2702906C2 (ru) | Птеридины в качестве fgfr ингибиторов | |
| JP6592197B2 (ja) | アクリル酸誘導体、製造方法、および医薬としてのその使用 | |
| JP5266219B2 (ja) | トリアゾリルフェニルベンゼンスルホンアミド類 | |
| JP2021506966A (ja) | Ｎｌｒｐ３インフラマソーム調節剤としてのスルホニル尿素誘導体 | |
| JP2023518830A (ja) | インダゾール系化合物及び関連使用方法 | |
| JP2023518831A (ja) | 変異ｌｒｒｋ２タンパク質分解の選択的モジュレーター及び関連する使用方法 | |
| CN109415361B (zh) | 丙烯酸类衍生物及其制备方法和其在医药上的用途 | |
| JP6891262B2 (ja) | 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニルイミダゾ［４，５−ｂ］ピリジン−７−アミン誘導体 | |
| JP2009534458A (ja) | アミノ−エチル−アミノ−アリール（ａｅａａ）化合物およびそれらの使用 | |
| TW202246243A (zh) | 胺基嘧啶化合物及其使用方法 | |
| WO2013081094A1 (ja) | イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途 | |
| WO2022028556A1 (zh) | Cdk9抑制剂及其用途 | |
| HK1247923B (en) | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| HK1135091B (zh) | 三唑基苯基苯磺酰胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20170817 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191017 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6629884 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |